Lv61
2050 积分 2022-09-22 加入
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
22天前
已完结
Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy
22天前
已完结
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages
24天前
已完结
Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
2个月前
已完结
Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors
2个月前
已完结
A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation
2个月前
已完结
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6
3个月前
已完结
GPC-3 in Hepatocellular Carcinoma; A Novel Biomarker and Molecular Target
4个月前
已完结
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
4个月前
已完结
A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma
4个月前
已完结
皖公网安备34019202002308
